Il4i1 Knockout MC-38 Cell Line

The choice depends on whether you are studying Il4i1 (interleukin-4-induced 1, IL4-induced gene 1)'s role as a secreted L-amino acid oxidase or its emerging functions in tumor immunosuppression. The Knockout line is the standard tool for asking whether Il4i1 is required for these processes — Il4i1 is a secreted enzyme that oxidatively deaminates L-amino acids (particularly phenylalanine, tryptophan, and tyrosine), generating H₂O₂, ammonia, and α-keto acids. Tryptophan-derived indole-3-pyruvate from Il4i1 activates the aryl hydrocarbon receptor (AhR), driving immunosuppression. Overexpression is useful for studying Il4i1 in heterologous expression contexts. For tumor immunology research, the EDITGENE Il4i1 Knockout in MC-38 is highly relevant — MC-38 is a murine colon adenocarcinoma cell line widely used for syngeneic tumor immunology research in C57BL/6 mice, and Il4i1 has emerged as a major immunosuppressive tumor-intrinsic factor through AhR activation. Rescue with wild-type or catalytically-dead Il4i1 is the standard specificity control. The knockout is valuable for studying tumor immune evasion mechanisms, AhR-mediated immunosuppression, and emerging Il4i1-targeted immuno-oncology drug development — Il4i1 has been compared to IDO1 as a tryptophan-metabolism-based immunosuppression axis.

Primary applications: • Tryptophan metabolism: tryptophan and indole-3-pyruvate (I3P) levels by LC-MS to characterize Il4i1-dependent metabolite generation. • AhR activation: cellular AhR pathway target gene (CYP1A1, CYP1B1) expression analysis given I3P-mediated AhR activation. • Syngeneic tumor immunology: MC-38 implantation in C57BL/6 mice — Il4i1-null versus wild-type tumor growth comparison to characterize tumor-intrinsic Il4i1-mediated immune evasion. • Immune checkpoint inhibitor combination: anti-PD-1, anti-PD-L1 combination studies in Il4i1-deficient tumors to test synergy with Il4i1 loss. EDITGENE recommends this MC-38-based model for researchers investigating tumor-intrinsic immunosuppression mechanisms, AhR-mediated immune evasion, and Il4i1-targeted immuno-oncology therapeutic development.

Yes. Il4i1 rescue experiments are well-established for tumor immunology research: • Construct design: use a codon-modified Il4i1 sequence with a small C-terminal tag (FLAG, HA). Il4i1 has N-terminal signal peptide (secreted enzyme), FAD-binding domain, and substrate-binding pocket — preserve all elements. • Catalytically-dead rescue: FAD-binding residue mutations abolish L-amino acid oxidase activity and serve as the standard specificity control. • Secreted enzyme considerations: Il4i1 is secreted — rescue interpretation considers conditioned media transfer or co-culture studies. • In vivo syngeneic rescue: MC-38 cells with Il4i1 rescue can be implanted in C57BL/6 mice for tumor growth and immune profiling studies. • Functional readout: rescue should restore cellular indole-3-pyruvate generation and AhR pathway activation in TME-relevant contexts. MC-38-specific considerations: • MC-38 is a chemically induced murine colon adenocarcinoma cell line (C57BL/6 origin) — widely used for syngeneic tumor immunology research given its immunogenicity in immunocompetent C57BL/6 hosts. • Lentiviral transduction is supported with moderate efficiency; characterize basal MHC class I expression and immune marker profile before phenotypic studies. • MC-38 is responsive to immune checkpoint inhibitors, making it relevant for studying tumor-intrinsic immune evasion mechanisms.